<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123474</url>
  </required_header>
  <id_info>
    <org_study_id>CA180-034</org_study_id>
    <nct_id>NCT00123474</nct_id>
  </id_info>
  <brief_title>Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML</brief_title>
  <official_title>A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia
      chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant
      to imatinib mesylate (Gleevec).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up</measure>
    <time_frame>6 months</time_frame>
    <description>Cytogenetic response (CyR) was based on the number of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With MCyR At or Prior to 24 Months Follow-Up</measure>
    <time_frame>24 months</time_frame>
    <description>CyR was based on the number of Ph+ metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: CCyR: 0% Ph+ cells in metaphase in BM; PCyR: &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR. Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up</measure>
    <time_frame>6 months, 24 months</time_frame>
    <description>A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MCyR in Participants With MCyR at 6 Months Follow-Up</measure>
    <time_frame>6 months</time_frame>
    <description>Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CHR in Participants With CHR at 6 Months Follow-Up</measure>
    <time_frame>6 months</time_frame>
    <description>Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MCyR in Participants With MCyR at 24 Months Follow-Up</measure>
    <time_frame>24 months</time_frame>
    <description>Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CHR in Participants With CHR At 24 Months Follow-Up</measure>
    <time_frame>24 months</time_frame>
    <description>Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MCyR Whose Disease Progressed by 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Progression in a participant=participant achieved a CHR and no longer met the criteria consistently over consecutive 2-weeks after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to &gt;20,000/mm^3 or an increase by &gt; 50,000/mm^3 on two assessments performed at least 2 weeks apart; participant met criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of MCyR, medium duration of MCyR could not be estimated because the majority of participants with MCyR continued to respond, or could not be reliably estimated because of the large number of censored participants. Cytogenetic assessments were not done after the 24 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CHR Whose Disease Progressed by 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Progression in a participant=achieved a CHR and subsequently no longer met the criteria consistently over a consecutive 2-week period after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to &gt;20,000/mm^3 or an increase by &gt; 50,000/mm^3 on two assessments performed at least 2 weeks apart; met the criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of CHR, medium duration of CHR could not be estimated because the majority of participants with CHR continued to respond, or could not be reliably estimated because of the large number of censored participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>BCR-ABL mutations were assessed in participants prior to the start of study drug (baseline) and at the time of disease progression or at end of therapy. Quantification of BCR-ABL transcripts in peripheral blood was evaluated using quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR, RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up</measure>
    <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
    <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up</measure>
    <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
    <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose</measure>
    <time_frame>6 months, 24 months</time_frame>
    <description>CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; PCyR: &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up</measure>
    <time_frame>6 months, 24 months</time_frame>
    <description>A CHR was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up</measure>
    <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
    <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up</measure>
    <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
    <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 6 Months Follow-Up</measure>
    <time_frame>6 months</time_frame>
    <description>Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up</measure>
    <time_frame>24 months</time_frame>
    <description>Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. No cytogenic assessments were made after 2 years of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants</measure>
    <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
    <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants</measure>
    <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
    <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Treatment Discontinuation at 24 Months of Follow-up</measure>
    <time_frame>Baseline to 30 days post last dose, up to 24 months</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led toTreatment Discontinuation After 7 Year Follow-up</measure>
    <time_frame>Baseline to 30 days post last dose, up to 7 years (study closure July 2014)</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants. After the 2-year analysis and Protocol Amendment 02, those on a BID dosing schedule were allowed to switch to a QD dosing schedule. Due to the large number of participants switching from BID dosing to QD dosing, the abbreviated dosing data collection method incorporated in Amendment 03, the overall safety data are presented for the 100 mg QD group and combined for the other treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">724</enrollment>
  <condition>Myeloid Leukemia, Chronic, Chronic-Phase</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Tablets, Oral, 50 mg BID, indefinitely, survival study</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sprycel</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Tablets, Oral, 70 mg BID, indefinitely, survival study</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sprycel</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Tablets, Oral, 100 mg QD, indefinitely, survival study</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Sprycel</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Tablets, Oral, 140 mg QD, indefinitely, survival study</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Sprycel</other_name>
    <other_name>BMS-354825</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Subjects with Philadelphia chromosome positive (Ph+) (or BCR/ABL+) chronic phase
             chronic myeloid leukemia whose disease has primary or acquired hematologic resistance
             to imatinib mesylate or who are intolerant of imatinib mesylate.

          -  Men and women, 18 years or older

          -  Adequate hepatic function

          -  Adequate renal function

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for a period of at least 1
             month before and at least 3 months after the study in such a manner that the risk of
             pregnancy is minimized.

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Subjects who are eligible and willing to undergo transplantation during the screening
             period

          -  A serious uncontrolled medical disorder or active infection that would impair the
             ability of the subject to receive protocol therapy

          -  Uncontrolled or significant cardiovascular disease

          -  Medications that increase bleeding risk

          -  Medications that change heart rhythms

          -  Dementia or altered mental status that would prohibit the understanding or rendering
             of informed consent

          -  History of significant bleeding disorder unrelated to CML

          -  Concurrent incurable malignancy other than CML

          -  Evidence of organ dysfunction or digestive dysfunction that would prevent
             administration of study therapy

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hematology Oncology Medical Group Inc.</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucla Dept. Of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology-Oncology Specialists</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute At Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School Of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Hospital System Inc.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School Of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates Of Central Illinois, Pc</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Faber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devetten, Marcel</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center At Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of North Carolina At Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ut Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1221</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <zip>1280</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>WA 6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>B-leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>CEP - Campinas</city>
        <zip>13083</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Paulo, Sp</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05652</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 2</city>
        <zip>128 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cedex</city>
        <state>Pierre Benite</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt/main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Co Galway</city>
        <state>Galway</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramat-gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monza (mi)</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kyunggi-do</city>
        <zip>480-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Distrito Federal</city>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jesus Maria</city>
        <state>Lima</state>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gdansk</city>
        <zip>80 211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Katowice</city>
        <zip>40032</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>31501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lodz</city>
        <zip>93510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20 950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warsaw</city>
        <zip>02097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St.petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groenkloof</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parktown</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Observatory</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 2XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newcastle</city>
        <state>Tyne And Wear</state>
        <zip>NE2 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Greece</country>
    <country>Thailand</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <reference>
    <citation>Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010 Jan 15;116(2):377-86. doi: 10.1002/cncr.24734.</citation>
    <PMID>19924787</PMID>
  </reference>
  <reference>
    <citation>Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009 Dec 3;114(24):4944-53. doi: 10.1182/blood-2009-04-214221. Epub 2009 Sep 24.</citation>
    <PMID>19779040</PMID>
  </reference>
  <reference>
    <citation>Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12. doi: 10.1200/JCO.2007.14.9260. Epub 2008 Jun 9.</citation>
    <PMID>18541900</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2005</study_first_posted>
  <results_first_submitted>June 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2015</results_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Phase Chronic Myelogenous Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study initiated July 2005 and completed July 2014.</recruitment_details>
      <pre_assignment_details>724 participants were enrolled, 670 were randomized, and 662 were treated with study drug. Reasons for non-randomization: 38 no longer met criteria, 8 other reasons, 7 withdrew consent, and 1 death.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib 100 mg QD</title>
          <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
        </group>
        <group group_id="P2">
          <title>Dasatinib 140 mg QD</title>
          <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
        </group>
        <group group_id="P3">
          <title>Dasatinib 50 mg BID</title>
          <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
        </group>
        <group group_id="P4">
          <title>Dasatinib 70 mg BID</title>
          <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized to Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="168"/>
                <participants group_id="P4" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized, never treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>As Treated at Study Closure</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165">Randomized to 50 mg BID but received 100 mg QD.</participants>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">Randomized to 100 mg QD but received 50 mg BID.</participants>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="167"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not reported when site closed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Request</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-specified</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Drug Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants randomized to a treatment arm are summarized.</population>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib 100 mg QD</title>
          <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
        </group>
        <group group_id="B2">
          <title>Dasatinib 140 mg QD</title>
          <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
        </group>
        <group group_id="B3">
          <title>Dasatinib 50 mg BID</title>
          <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
        </group>
        <group group_id="B4">
          <title>Dasatinib 70 mg BID</title>
          <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="168"/>
            <count group_id="B5" value="670"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than, equal to (&lt;=) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than (&gt;) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Imatinib Status</title>
          <description>Primary Resistance: no decrease in white blood cell (WBC) count after ≥ 4 weeks imatinib or not achieved a complete hematologic response (CHR) after 3 months, a major cytogenetic response (MCyR) after 6 months, or a complete cytogenetic response (CCyR) after 12 months. Acquired resistance: achieved MCyR and no longer met the criteria for MCyR. Intolerance: Grade ≥ 3 toxicity considered at least possibly related to imatinib at a dose of ≤ 400 mg/day which led to discontinuation of therapy; tolerated the dose of 400 mg but did not achieve a CCyR and subsequently did not tolerate doses ≥ 600 mg.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary Resistance to Imatinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acquired Resistance to Imatinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intolerant to Imatinib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up</title>
        <description>Cytogenetic response (CyR) was based on the number of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.</description>
        <time_frame>6 months</time_frame>
        <population>All randomized imatinib-resistant participants with available data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>QD Dasatinib</title>
            <description>Participants received either 100 mg or 140 mg once a day (QD) dasatinib until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>BID Dasatinib</title>
            <description>Participants received either 50 mg or 70 mg twice a day (BID) dasatinib until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up</title>
          <description>Cytogenetic response (CyR) was based on the number of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.</description>
          <population>All randomized imatinib-resistant participants with available data were summarized.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="45.4" upper_limit="58.2"/>
                    <measurement group_id="O2" value="49.0" lower_limit="42.7" upper_limit="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>6 Month Analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% confidence interval (CI) for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With MCyR At or Prior to 24 Months Follow-Up</title>
        <description>CyR was based on the number of Ph+ metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: CCyR: 0% Ph+ cells in metaphase in BM; PCyR: &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR. Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized imatinib-resistant participants with available data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib QD</title>
            <description>Participants received either 100 mg QD or 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib BID</title>
            <description>Participants received either 50 mg BID or 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 100 mg Total Daily Dose</title>
            <description>Participants received 100 mg as a total daily dose (either 50 mg BID or 100 mg QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 140 mg Total Daily Dose</title>
            <description>Participants received 140 mg as a total daily dose (either 70 mg BID or 140 mg QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With MCyR At or Prior to 24 Months Follow-Up</title>
          <description>CyR was based on the number of Ph+ metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: CCyR: 0% Ph+ cells in metaphase in BM; PCyR: &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR. Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.</description>
          <population>All randomized imatinib-resistant participants with available data were summarized.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="248"/>
                <count group_id="O4" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" lower_limit="51.9" upper_limit="64.5"/>
                    <measurement group_id="O2" value="56.4" lower_limit="50.0" upper_limit="62.6"/>
                    <measurement group_id="O3" value="57.3" lower_limit="50.8" upper_limit="63.5"/>
                    <measurement group_id="O4" value="57.4" lower_limit="51.0" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% CI for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of 100 mg total daily dose relative to 140 mg total daily dose was deduced if the lower bound of the 95% CI for the difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up</title>
        <description>A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
        <time_frame>6 months, 24 months</time_frame>
        <population>All randomized imatinib-resistant participants with available data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up</title>
          <description>A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
          <population>All randomized imatinib-resistant participants with available data were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="79.0" upper_limit="91.8"/>
                    <measurement group_id="O2" value="85.4" lower_limit="77.9" upper_limit="91.1"/>
                    <measurement group_id="O3" value="91.1" lower_limit="84.7" upper_limit="95.5"/>
                    <measurement group_id="O4" value="87.4" lower_limit="80.3" upper_limit="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month (n=124,123,124,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="81.8" upper_limit="93.7"/>
                    <measurement group_id="O2" value="86.2" lower_limit="78.8" upper_limit="91.7"/>
                    <measurement group_id="O3" value="91.9" lower_limit="85.7" upper_limit="96.1"/>
                    <measurement group_id="O4" value="88.9" lower_limit="82.1" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to MCyR in Participants With MCyR at 6 Months Follow-Up</title>
        <description>Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders).</description>
        <time_frame>6 months</time_frame>
        <population>Randomized imatinib-resistant participants with MCyR and available data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to MCyR in Participants With MCyR at 6 Months Follow-Up</title>
          <description>Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders).</description>
          <population>Randomized imatinib-resistant participants with MCyR and available data were summarized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.8" upper_limit="2.9"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.8" upper_limit="2.9"/>
                    <measurement group_id="O4" value="2.8" lower_limit="2.8" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CHR in Participants With CHR at 6 Months Follow-Up</title>
        <description>Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders).</description>
        <time_frame>6 months</time_frame>
        <population>Randomized imatinib-resistant participants with CHR and available data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CHR in Participants With CHR at 6 Months Follow-Up</title>
          <description>Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders).</description>
          <population>Randomized imatinib-resistant participants with CHR and available data were summarized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.5" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.6" upper_limit="0.9"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.5" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to MCyR in Participants With MCyR at 24 Months Follow-Up</title>
        <description>Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized imatinib-resistant participants with MCyR were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to MCyR in Participants With MCyR at 24 Months Follow-Up</title>
          <description>Time to MCyR was defined as the time from the first dosing date until criteria were first met for CCyR or PCyR, whichever occurred first. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to MCyR response for responders and time to last cytogenetic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up.</description>
          <population>Randomized imatinib-resistant participants with MCyR were summarized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.8" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.8" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.9" lower_limit="2.8" upper_limit="3.3"/>
                    <measurement group_id="O4" value="2.9" lower_limit="2.8" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CHR in Participants With CHR At 24 Months Follow-Up</title>
        <description>Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up.</description>
        <time_frame>24 months</time_frame>
        <population>Randomized imatinib-resistant participants with CHR were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CHR in Participants With CHR At 24 Months Follow-Up</title>
          <description>Time to CHR was defined as the time from the first dosing date until criteria are first met for the response. Non-responders were censored at the maximum time of all participants in their respective group (ie, maximum between time to CHR response for responders and time to last hematologic assessment for non-responders). Cytogenetic assessments were not done after the 2 Year Follow-up.</description>
          <population>Randomized imatinib-resistant participants with CHR were summarized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.5" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.5" upper_limit="0.9"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.5" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MCyR Whose Disease Progressed by 24 Months</title>
        <description>Progression in a participant=participant achieved a CHR and no longer met the criteria consistently over consecutive 2-weeks after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to &gt;20,000/mm^3 or an increase by &gt; 50,000/mm^3 on two assessments performed at least 2 weeks apart; participant met criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of MCyR, medium duration of MCyR could not be estimated because the majority of participants with MCyR continued to respond, or could not be reliably estimated because of the large number of censored participants. Cytogenetic assessments were not done after the 24 month follow-up.</description>
        <time_frame>24 months</time_frame>
        <population>All imatinib-resistant participants who had achieved MCyR and experienced disease progression were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MCyR Whose Disease Progressed by 24 Months</title>
          <description>Progression in a participant=participant achieved a CHR and no longer met the criteria consistently over consecutive 2-weeks after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to &gt;20,000/mm^3 or an increase by &gt; 50,000/mm^3 on two assessments performed at least 2 weeks apart; participant met criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of MCyR, medium duration of MCyR could not be estimated because the majority of participants with MCyR continued to respond, or could not be reliably estimated because of the large number of censored participants. Cytogenetic assessments were not done after the 24 month follow-up.</description>
          <population>All imatinib-resistant participants who had achieved MCyR and experienced disease progression were summarized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CHR Whose Disease Progressed by 24 Months</title>
        <description>Progression in a participant=achieved a CHR and subsequently no longer met the criteria consistently over a consecutive 2-week period after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to &gt;20,000/mm^3 or an increase by &gt; 50,000/mm^3 on two assessments performed at least 2 weeks apart; met the criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of CHR, medium duration of CHR could not be estimated because the majority of participants with CHR continued to respond, or could not be reliably estimated because of the large number of censored participants.</description>
        <time_frame>24 months</time_frame>
        <population>All imatinib-resistant participants who achieved CHR and then experienced disease progression were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CHR Whose Disease Progressed by 24 Months</title>
          <description>Progression in a participant=achieved a CHR and subsequently no longer met the criteria consistently over a consecutive 2-week period after starting their maximum dose; had no CHR after receiving their maximum dose and had an increase in white blood count (WBC) defined as a doubling of the count from the lowest value to &gt;20,000/mm^3 or an increase by &gt; 50,000/mm^3 on two assessments performed at least 2 weeks apart; met the criteria of accelerated or blast phase CML at any time; had a MCyR and subsequently no longer met the criteria for MCyR after starting their maximum dose; had a ≥ 30% absolute increase in the number of Ph+ metaphases. Although a related secondary endpoint was estimated duration of CHR, medium duration of CHR could not be estimated because the majority of participants with CHR continued to respond, or could not be reliably estimated because of the large number of censored participants.</description>
          <population>All imatinib-resistant participants who achieved CHR and then experienced disease progression were summarized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="114"/>
                <count group_id="O4" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants</title>
        <description>BCR-ABL mutations were assessed in participants prior to the start of study drug (baseline) and at the time of disease progression or at end of therapy. Quantification of BCR-ABL transcripts in peripheral blood was evaluated using quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR, RT-PCR).</description>
        <time_frame>Baseline up to 24 months</time_frame>
        <population>All randomized, treated participants with available mutation data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MCyR and Baseline BCR-ABL Gene Mutation - All Treated Participants</title>
          <description>BCR-ABL mutations were assessed in participants prior to the start of study drug (baseline) and at the time of disease progression or at end of therapy. Quantification of BCR-ABL transcripts in peripheral blood was evaluated using quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR, RT-PCR).</description>
          <population>All randomized, treated participants with available mutation data were summarized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Imatinib-resistant Mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutations with unknown Imatinib-resistance status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imatinib Resistant or unknown mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polymorphisms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Mutations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up</title>
        <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
        <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
        <population>All randomized imatinib-resistant participants were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Imatinib-Resistant Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up</title>
          <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
          <population>All randomized imatinib-resistant participants were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Months (n=124,123,124, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="66.3" upper_limit="82.1"/>
                    <measurement group_id="O2" value="61.3" lower_limit="52.7" upper_limit="69.6"/>
                    <measurement group_id="O3" value="70.3" lower_limit="60.8" upper_limit="77.9"/>
                    <measurement group_id="O4" value="70.8" lower_limit="61.6" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=124,123,124, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="55.2" upper_limit="72.9"/>
                    <measurement group_id="O2" value="47.4" lower_limit="37.7" upper_limit="56.5"/>
                    <measurement group_id="O3" value="67.1" lower_limit="57.3" upper_limit="75.1"/>
                    <measurement group_id="O4" value="58.2" lower_limit="48.4" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=124,123,124, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="48.0" upper_limit="66.5"/>
                    <measurement group_id="O2" value="40.0" lower_limit="30.6" upper_limit="49.3"/>
                    <measurement group_id="O3" value="63.8" lower_limit="53.7" upper_limit="72.2"/>
                    <measurement group_id="O4" value="55.1" lower_limit="45.2" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=124,123,124, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" lower_limit="40.2" upper_limit="59.3"/>
                    <measurement group_id="O2" value="36.4" lower_limit="27.1" upper_limit="45.8"/>
                    <measurement group_id="O3" value="57.4" lower_limit="46.9" upper_limit="66.5"/>
                    <measurement group_id="O4" value="50.2" lower_limit="40.2" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Months (n=124,123,124, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="34.0" upper_limit="53.6"/>
                    <measurement group_id="O2" value="31.4" lower_limit="22.4" upper_limit="40.8"/>
                    <measurement group_id="O3" value="50.7" lower_limit="40.0" upper_limit="60.4"/>
                    <measurement group_id="O4" value="45.3" lower_limit="35.2" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Months (n=124,123,124, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="29.2" upper_limit="48.7"/>
                    <measurement group_id="O2" value="30.2" lower_limit="21.2" upper_limit="39.6"/>
                    <measurement group_id="O3" value="42.1" lower_limit="31.5" upper_limit="52.4"/>
                    <measurement group_id="O4" value="41.3" lower_limit="31.3" upper_limit="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up</title>
        <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
        <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
        <population>All randomized imatinib-resistant participants were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Imatinib-Resistant Participants With Overall Survival (OS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up</title>
          <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
          <population>All randomized imatinib-resistant participants were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="83.2" upper_limit="94.2"/>
                    <measurement group_id="O2" value="93.9" lower_limit="87.6" upper_limit="97.0"/>
                    <measurement group_id="O3" value="88.9" lower_limit="81.6" upper_limit="93.4"/>
                    <measurement group_id="O4" value="85.1" lower_limit="77.3" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="80.2" upper_limit="92.3"/>
                    <measurement group_id="O2" value="83.8" lower_limit="75.6" upper_limit="89.5"/>
                    <measurement group_id="O3" value="83.5" lower_limit="75.3" upper_limit="89.1"/>
                    <measurement group_id="O4" value="76.5" lower_limit="67.7" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" lower_limit="71.3" upper_limit="85.9"/>
                    <measurement group_id="O2" value="82.0" lower_limit="73.4" upper_limit="88.0"/>
                    <measurement group_id="O3" value="80.7" lower_limit="72.1" upper_limit="86.9"/>
                    <measurement group_id="O4" value="71.1" lower_limit="61.9" upper_limit="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" lower_limit="66.1" upper_limit="82.0"/>
                    <measurement group_id="O2" value="78.0" lower_limit="68.9" upper_limit="84.7"/>
                    <measurement group_id="O3" value="73.6" lower_limit="64.1" upper_limit="80.9"/>
                    <measurement group_id="O4" value="69.1" lower_limit="59.8" upper_limit="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="58.3" upper_limit="75.8"/>
                    <measurement group_id="O2" value="72.6" lower_limit="62.9" upper_limit="80.1"/>
                    <measurement group_id="O3" value="71.4" lower_limit="61.8" upper_limit="79.0"/>
                    <measurement group_id="O4" value="67.1" lower_limit="57.6" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Months (n=124,123,124,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" lower_limit="52.6" upper_limit="71.0"/>
                    <measurement group_id="O2" value="68.1" lower_limit="58.0" upper_limit="76.2"/>
                    <measurement group_id="O3" value="67.9" lower_limit="57.9" upper_limit="76.0"/>
                    <measurement group_id="O4" value="65.0" lower_limit="55.3" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose</title>
        <description>CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; PCyR: &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR.</description>
        <time_frame>6 months, 24 months</time_frame>
        <population>All randomized imatinib-intolerant participants with available data were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>QD Dasatinib</title>
            <description>Participants received either 100 mg or 140 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>BID Dasatinib</title>
            <description>Participants received either 50 mg or 70 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Total Daily Dose 100 mg</title>
            <description>Participants received either 100 mg QD or 50 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O4">
            <title>Total Daily Dose 140 mg</title>
            <description>Participants received either 140 mg QD or 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose</title>
          <description>CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; PCyR: &gt;0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: &gt;35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: &gt;65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: &gt;95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR.</description>
          <population>All randomized imatinib-intolerant participants with available data were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" lower_limit="61.8" upper_limit="81.5"/>
                    <measurement group_id="O2" value="70.6" lower_limit="59.7" upper_limit="80.0"/>
                    <measurement group_id="O3" value="73.6" lower_limit="63.0" upper_limit="82.4"/>
                    <measurement group_id="O4" value="69.4" lower_limit="58.5" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="66.8" upper_limit="85.4"/>
                    <measurement group_id="O2" value="75.6" lower_limit="65.1" upper_limit="84.2"/>
                    <measurement group_id="O3" value="77.0" lower_limit="66.8" upper_limit="85.4"/>
                    <measurement group_id="O4" value="75.6" lower_limit="65.1" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>6 Month Analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% CI for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 Month Analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of 100 mg QD Total Daily Dose relative to 140 mg QD Total Daily Dose was deduced if the lower bound of the 95% CI difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 Month Analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% CI for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 Month Analysis</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of 100 mg QD Total Daily Dose relative to 140 mg QD Total Daily Dose was deduced if the lower bound of the 95% CI difference was greater than or equal to -15%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up</title>
        <description>A CHR was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
        <time_frame>6 months, 24 months</time_frame>
        <population>All randomized imatinib-intolerant participants were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up</title>
          <description>A CHR was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
          <population>All randomized imatinib-intolerant participants were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months (n=43,44,44,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up</title>
        <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
        <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
        <population>All randomized imatinib-intolerant participants with available data were summarized</population>
        <group_list>
          <group group_id="O1">
            <title>100mg QD</title>
            <description>Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>140mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
          </group>
          <group group_id="O3">
            <title>50mg BID</title>
            <description>Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
          </group>
          <group group_id="O4">
            <title>70mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Imatinib Intolerant Participants With Progression Free Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-Up</title>
          <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
          <population>All randomized imatinib-intolerant participants with available data were summarized</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="67.0" upper_limit="92.3"/>
                    <measurement group_id="O2" value="87.7" lower_limit="72.8" upper_limit="94.7"/>
                    <measurement group_id="O3" value="77.4" lower_limit="61.0" upper_limit="87.6"/>
                    <measurement group_id="O4" value="83.7" lower_limit="67.1" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="53.6" upper_limit="83.7"/>
                    <measurement group_id="O2" value="76.0" lower_limit="58.7" upper_limit="86.8"/>
                    <measurement group_id="O3" value="68.6" lower_limit="51.1" upper_limit="80.9"/>
                    <measurement group_id="O4" value="77.4" lower_limit="59.6" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="44.5" upper_limit="76.5"/>
                    <measurement group_id="O2" value="76.0" lower_limit="58.7" upper_limit="86.8"/>
                    <measurement group_id="O3" value="62.0" lower_limit="44.1" upper_limit="75.7"/>
                    <measurement group_id="O4" value="66.9" lower_limit="47.8" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="40.8" upper_limit="73.6"/>
                    <measurement group_id="O2" value="71.2" lower_limit="52.1" upper_limit="83.8"/>
                    <measurement group_id="O3" value="62.0" lower_limit="44.1" upper_limit="75.7"/>
                    <measurement group_id="O4" value="59.5" lower_limit="40.1" upper_limit="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="40.8" upper_limit="73.6"/>
                    <measurement group_id="O2" value="66.5" lower_limit="46.3" upper_limit="80.6"/>
                    <measurement group_id="O3" value="58.2" lower_limit="39.8" upper_limit="72.7"/>
                    <measurement group_id="O4" value="55.2" lower_limit="35.7" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="32.1" upper_limit="67.0"/>
                    <measurement group_id="O2" value="66.5" lower_limit="46.3" upper_limit="80.6"/>
                    <measurement group_id="O3" value="47.5" lower_limit="27.4" upper_limit="65.2"/>
                    <measurement group_id="O4" value="50.2" lower_limit="30.4" upper_limit="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up</title>
        <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
        <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
        <population>All randomized imatinib-intolerant participants were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>100mg QD</title>
            <description>Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>140mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
          </group>
          <group group_id="O3">
            <title>50mg BID</title>
            <description>Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
          </group>
          <group group_id="O4">
            <title>70mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up</title>
          <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
          <population>All randomized imatinib-intolerant participants were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="81.2" upper_limit="98.7"/>
                    <measurement group_id="O2" value="92.8" lower_limit="79.2" upper_limit="97.6"/>
                    <measurement group_id="O3" value="95.3" lower_limit="82.5" upper_limit="98.8"/>
                    <measurement group_id="O4" value="97.4" lower_limit="82.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="74.9" upper_limit="96.0"/>
                    <measurement group_id="O2" value="92.8" lower_limit="79.2" upper_limit="97.6"/>
                    <measurement group_id="O3" value="90.4" lower_limit="76.4" upper_limit="96.3"/>
                    <measurement group_id="O4" value="94.7" lower_limit="80.6" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="68.6" upper_limit="92.7"/>
                    <measurement group_id="O2" value="87.5" lower_limit="72.4" upper_limit="94.6"/>
                    <measurement group_id="O3" value="85.1" lower_limit="69.7" upper_limit="93.0"/>
                    <measurement group_id="O4" value="86.8" lower_limit="71.2" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="65.6" upper_limit="90.9"/>
                    <measurement group_id="O2" value="87.5" lower_limit="72.4" upper_limit="94.6"/>
                    <measurement group_id="O3" value="82.4" lower_limit="66.6" upper_limit="91.2"/>
                    <measurement group_id="O4" value="81.1" lower_limit="64.3" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" lower_limit="62.3" upper_limit="88.9"/>
                    <measurement group_id="O2" value="87.5" lower_limit="72.4" upper_limit="94.6"/>
                    <measurement group_id="O3" value="79.6" lower_limit="63.2" upper_limit="89.3"/>
                    <measurement group_id="O4" value="81.1" lower_limit="64.3" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Months (n=43,44,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="52.2" upper_limit="82.2"/>
                    <measurement group_id="O2" value="87.5" lower_limit="72.4" upper_limit="94.6"/>
                    <measurement group_id="O3" value="76.6" lower_limit="59.7" upper_limit="87.2"/>
                    <measurement group_id="O4" value="77.7" lower_limit="60.1" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 6 Months Follow-Up</title>
        <description>Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
        <time_frame>6 months</time_frame>
        <population>All randomized participants were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>QD Dasatinib</title>
            <description>Participants received either 100 mg or 140 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>BID Dasatinib</title>
            <description>Participants received either 50 mg or 70 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Total Daily Dose 100 mg</title>
            <description>Participants received either 100 mg QD or 50 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O4">
            <title>Total Daily Dose 140 mg</title>
            <description>Participants received either 140 mg QD or 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 6 Months Follow-Up</title>
          <description>Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.</description>
          <population>All randomized participants were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCyR (n=334,336,335,335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" lower_limit="51.7" upper_limit="62.6"/>
                    <measurement group_id="O2" value="54.5" lower_limit="49.0" upper_limit="59.9"/>
                    <measurement group_id="O3" value="56.1" lower_limit="50.6" upper_limit="61.5"/>
                    <measurement group_id="O4" value="55.5" lower_limit="50.0" upper_limit="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHR(n=334,336,335,335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="83.7" upper_limit="91.0"/>
                    <measurement group_id="O2" value="89.3" lower_limit="85.5" upper_limit="92.4"/>
                    <measurement group_id="O3" value="90.7" lower_limit="87.1" upper_limit="93.6"/>
                    <measurement group_id="O4" value="86.3" lower_limit="82.1" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up</title>
        <description>Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. No cytogenic assessments were made after 2 years of follow-up.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized participants were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>QD Dasatinib</title>
            <description>Participants received either 100 mg or 140 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>BID Dasatinib</title>
            <description>Participants received either 50 mg or 70 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Total Daily Dose 100 mg</title>
            <description>Participants received either 100 mg QD or 50 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O4">
            <title>Total Daily Dose 140 mg</title>
            <description>Participants received either 140 mg QD or 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up</title>
          <description>Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): &gt;0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets &lt; 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); &lt; 5% myelocytes plus metamyelocytes in PB; Basophils in PB &lt; 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. No cytogenic assessments were made after 2 years of follow-up.</description>
          <population>All randomized participants were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="335"/>
                <count group_id="O4" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCyR(n=334,336,335,335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="57.8" upper_limit="68.4"/>
                    <measurement group_id="O2" value="61.3" lower_limit="55.9" upper_limit="66.5"/>
                    <measurement group_id="O3" value="62.4" lower_limit="57.0" upper_limit="67.6"/>
                    <measurement group_id="O4" value="62.1" lower_limit="56.7" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHR (n=334,336,335,335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" lower_limit="85.4" upper_limit="92.3"/>
                    <measurement group_id="O2" value="90.2" lower_limit="86.5" upper_limit="93.1"/>
                    <measurement group_id="O3" value="91.9" lower_limit="88.5" upper_limit="94.6"/>
                    <measurement group_id="O4" value="87.5" lower_limit="83.4" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants</title>
        <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
        <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
        <population>All participants who were randomized to a treatment arm were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Progression Free Survival (PFS) at 24, 36, 48, 60, 72, and 84 Months Follow-Up by Dose Schedule and Total Daily Dose - All Randomized Participants</title>
          <description>PFS= time from randomization until: CHR achieved and participant subsequently no longer met criteria for CHR over 2 weeks; no CHR after receiving maximum dose and an increase in WBC (ie, doubling of the count from the lowest value to &gt; 20,000/mm^3 or an increase by &gt; 50,000/mm^3 on 2 assessments performed 2 weeks apart); participant met criteria of accelerated phase or blast phase CML; participant had MCyR and subsequently no longer met criteria for MCyR after starting maximum dose; participant had a ≥ 30% absolute increase in number of Ph+ metaphases. Deaths without a reported prior progression were considered to have progressed on the date of death; those who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. When first progression reported during follow-up, it was censored at last on-study assessment. If the first progression reported during follow-up was death, participant considered to have progressed at date of death.</description>
          <population>All participants who were randomized to a treatment arm were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="69.9" upper_limit="83.2"/>
                    <measurement group_id="O2" value="67.7" lower_limit="59.6" upper_limit="74.5"/>
                    <measurement group_id="O3" value="72.2" lower_limit="64.3" upper_limit="78.7"/>
                    <measurement group_id="O4" value="73.9" lower_limit="66.1" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" lower_limit="58.3" upper_limit="73.6"/>
                    <measurement group_id="O2" value="54.0" lower_limit="45.4" upper_limit="61.8"/>
                    <measurement group_id="O3" value="67.5" lower_limit="59.2" upper_limit="74.5"/>
                    <measurement group_id="O4" value="62.8" lower_limit="54.3" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="50.6" upper_limit="66.6"/>
                    <measurement group_id="O2" value="48.0" lower_limit="39.4" upper_limit="56.2"/>
                    <measurement group_id="O3" value="63.3" lower_limit="54.8" upper_limit="70.7"/>
                    <measurement group_id="O4" value="58.7" lower_limit="50.1" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="43.8" upper_limit="60.5"/>
                    <measurement group_id="O2" value="44.2" lower_limit="35.5" upper_limit="52.5"/>
                    <measurement group_id="O3" value="58.7" lower_limit="49.8" upper_limit="66.5"/>
                    <measurement group_id="O4" value="52.5" lower_limit="43.7" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="39.2" upper_limit="56.2"/>
                    <measurement group_id="O2" value="39.2" lower_limit="30.6" upper_limit="47.7"/>
                    <measurement group_id="O3" value="52.8" lower_limit="43.7" upper_limit="61.1"/>
                    <measurement group_id="O4" value="47.7" lower_limit="38.7" upper_limit="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="33.4" upper_limit="50.6"/>
                    <measurement group_id="O2" value="38.2" lower_limit="29.6" upper_limit="46.7"/>
                    <measurement group_id="O3" value="43.9" lower_limit="34.5" upper_limit="52.9"/>
                    <measurement group_id="O4" value="43.5" lower_limit="34.5" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants</title>
        <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
        <time_frame>24, 36, 48, 60, 72, and 84 months</time_frame>
        <population>All participants who were randomized to a treatment arm were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Overall Survival at 24, 36, 48, 60, 72, and 84 Months Follow-Up - All Randomized Participants</title>
          <description>Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.</description>
          <population>All participants who were randomized to a treatment arm were summarized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="168"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="85.8" upper_limit="94.8"/>
                    <measurement group_id="O2" value="93.6" lower_limit="88.4" upper_limit="96.5"/>
                    <measurement group_id="O3" value="90.6" lower_limit="84.9" upper_limit="94.2"/>
                    <measurement group_id="O4" value="88.1" lower_limit="81.9" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" lower_limit="82.0" upper_limit="92.3"/>
                    <measurement group_id="O2" value="86.2" lower_limit="79.6" upper_limit="90.8"/>
                    <measurement group_id="O3" value="85.3" lower_limit="78.7" upper_limit="90.0"/>
                    <measurement group_id="O4" value="80.9" lower_limit="73.9" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="73.9" upper_limit="86.3"/>
                    <measurement group_id="O2" value="83.4" lower_limit="76.4" upper_limit="88.5"/>
                    <measurement group_id="O3" value="81.8" lower_limit="74.7" upper_limit="87.1"/>
                    <measurement group_id="O4" value="74.9" lower_limit="67.3" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" lower_limit="69.4" upper_limit="82.7"/>
                    <measurement group_id="O2" value="80.5" lower_limit="73.1" upper_limit="86.0"/>
                    <measurement group_id="O3" value="75.9" lower_limit="68.2" upper_limit="82.0"/>
                    <measurement group_id="O4" value="72.0" lower_limit="64.1" upper_limit="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" lower_limit="62.9" upper_limit="77.5"/>
                    <measurement group_id="O2" value="76.6" lower_limit="68.7" upper_limit="82.7"/>
                    <measurement group_id="O3" value="73.6" lower_limit="65.6" upper_limit="80.0"/>
                    <measurement group_id="O4" value="70.5" lower_limit="62.5" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Months (n=167, 167, 168, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="56.1" upper_limit="71.8"/>
                    <measurement group_id="O2" value="73.4" lower_limit="65.2" upper_limit="79.9"/>
                    <measurement group_id="O3" value="70.3" lower_limit="62.0" upper_limit="77.1"/>
                    <measurement group_id="O4" value="68.1" lower_limit="59.8" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Treatment Discontinuation at 24 Months of Follow-up</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants.</description>
        <time_frame>Baseline to 30 days post last dose, up to 24 months</time_frame>
        <population>All randomized participants who received at least one dose of study drug were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib 100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Dasatinib 140 mg QD</title>
            <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O3">
            <title>Dasatinib 50 mg BID</title>
            <description>Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
          <group group_id="O4">
            <title>Dasatinib 70 mg BID</title>
            <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Treatment Discontinuation at 24 Months of Follow-up</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants.</description>
          <population>All randomized participants who received at least one dose of study drug were summarized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related AEs that led to discontinuationt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death within 30 days of last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led toTreatment Discontinuation After 7 Year Follow-up</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants. After the 2-year analysis and Protocol Amendment 02, those on a BID dosing schedule were allowed to switch to a QD dosing schedule. Due to the large number of participants switching from BID dosing to QD dosing, the abbreviated dosing data collection method incorporated in Amendment 03, the overall safety data are presented for the 100 mg QD group and combined for the other treatment groups.</description>
        <time_frame>Baseline to 30 days post last dose, up to 7 years (study closure July 2014)</time_frame>
        <population>All randomized participants who received at least one dose of study drug were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg QD</title>
            <description>Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
          <group group_id="O2">
            <title>Other Treatment Groups</title>
            <description>Participants participated in all other treatment arms until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants received study drug in any schedule or total daily dose until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) That Led toTreatment Discontinuation After 7 Year Follow-up</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Baseline=closest to, but no later than, the first day of study drug for treated participants. After the 2-year analysis and Protocol Amendment 02, those on a BID dosing schedule were allowed to switch to a QD dosing schedule. Due to the large number of participants switching from BID dosing to QD dosing, the abbreviated dosing data collection method incorporated in Amendment 03, the overall safety data are presented for the 100 mg QD group and combined for the other treatment groups.</description>
          <population>All randomized participants who received at least one dose of study drug were summarized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths on-study or within 30 days post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="259"/>
                    <measurement group_id="O3" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 30 days post last dose, up to 7 years (study closure July 2014)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>100mg QD</title>
          <description>Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant’s decision to withdraw.
After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.</description>
        </group>
        <group group_id="E2">
          <title>140mg QD</title>
          <description>Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
        </group>
        <group group_id="E3">
          <title>50mg BID</title>
          <description>Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
        </group>
        <group group_id="E4">
          <title>70mg BID</title>
          <description>Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Blast cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia transformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Skin cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Blast cell crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Blast cell proliferation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Blast crisis in myelogenous leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Alveolar proteinosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

